NasdaqGM - Delayed Quote USD

EDAP TMS S.A. (EDAP)

Compare
2.1000
-0.1000
(-4.55%)
At close: January 10 at 4:00:01 PM EST

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Ryan Rhodes CEO & Director -- -- 1962
Mr. Ken Mobeck Chief Financial Officer -- -- 1971
Mr. Carre Emmanuel Chief Operating Officer -- -- --
Mr. Francois Dietsch Chief Accounting Officer -- -- 1976
Ms. Blandine Confort Head of Legal Affairs & Investor Relations and Secretary -- -- --
Mr. Frederic Pech President of EDAP TMS France -- -- 1969
Mr. Jean-Francois Bachelard President & Chief Executive Officer of Edaptechnomed Co. Ltd. -- -- 1964

EDAP TMS S.A.

Parc dActivites la Poudrette-Lamartine
4/6, rue du DauphinE Vaulx-en-Velin
Lyon, 69120
France
33 4 72 153 150 https://www.edap-tms.com
Sector: 
Healthcare
Full Time Employees: 
307

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.

Corporate Governance

EDAP TMS S.A.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 7, 2024 at 12:00 PM UTC

EDAP TMS S.A. Earnings Date

Recent Events

January 10, 2025 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

December 4, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

November 19, 2024 at 8:30 AM UTC

at Jefferies London Healthcare Conference

November 7, 2024 at 1:30 PM UTC

Q3 2024 Earnings Call

August 22, 2024 at 12:00 AM UTC

S-8: Offering Registrations

July 19, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

July 8, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

June 7, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

May 16, 2024 at 12:00 AM UTC

6-K: Corporate Changes & Voting Matters

April 12, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission